Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 201 abstracts

no pagination
Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head & neck. 2002 May;24(5):437-42.
Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Statistics in medicine. 2001 Jul 30;20(14):2079-90.
Bast RC, Mills GB, Young RC. Translational research--traffic on the bridge. Biomed Pharmacother. 2001 Nov;55(9-10):565-71.
Chen ZS, Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T, Okumura H, Ren XQ, Belinsky MG, Lee K, Kruh GD, Kobayashi M, Akiyama S. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. International journal of cancer. 2001 Jul;93(1):107-13.
Cornfeld MJ, Jadwin A, O'Grady P, Babb J, Engstrom PF. Feasibility of assessing quality in medical oncology practices. Cancer Pract. 2001 Sep;9(5):231-5.
Davis W, Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. The Journal of pharmacology and experimental therapeutics. 2001 Jan;296(1):1-6.
Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001 Jan;7(1):153-7.
Langer CJ. The emerging world role of irinotecan in lung cancer. Oncology (Huntingt). 2001 Jul;15(7 Suppl 8):15-21.
Langer CJ. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. Lung Cancer. 2001 Nov;34(2):297-303.
Langer CJ. Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan. Oncology (Huntingt). 2001 Jan;15(1 Suppl 1):19-24.
Murphy BA, Leong T, Burkey B, Langer C, Forastiere A. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). Am J Clin Oncol. 2001 Feb;24(1):64-6.
O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May;19(9):2413-21.
Ranganathan S, McCauley RA, Dexter DW, Hudes GR. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Br J Cancer. 2001 Sep;85(5):735-40.
Sasson AR, Hoffman JP, Ross E, Meropol NJ, Szarka CE, Freedman G, Pinover W, Pingpank JF, Eisenberg BL. Trimodality therapy for advanced gallbladder cancer. Am Surg. 2001 Mar;67(3):277-83; discussion 284.
Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. The Journal of pharmacology and experimental therapeutics. 2001 Jun;297(3):1067-73.
Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001 Oct;7(10):3251-7.
Von Roenn JH, Cianfrocca M. Treatment of Kaposi's sarcoma. Cancer Treat Res. 2001 Jan;104:127-48.
Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001 Sep;22(9):1379-83.
Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt). 2000 May;14(5):719-29; discussion 729-31, 734, 737.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Human Antineoplastic Agents therapeutic use drug therapy US Gov't Support-PHS pharmacology pathology administration & dosage drug effects metabolism Non-US Gov't Support adverse effects Female Prognosis Male Paclitaxel therapy analogs & derivatives mortality Aged Treatment Outcome genetics Middle Age Drug Synergism Clinical Trials Non-Small-Cell Lung Carcinoma Cultured Tumor Cells Apoptosis Intravenous Infusions Doxorubicin United States Animal Lung Neoplasms Squamous Cell Carcinoma cytology Medical Oncology pharmacokinetics Adjuvant Radiotherapy Thiazoles Head and Neck Neoplasms Survival Analysis Survival Rate Fluorouracil Adult Mice Cisplatin enzymology Topotecan physiology use Drug Dose-Response Relationship Oral Administration Local Neoplasm Recurrence Transcription Factors therapeutic Leucovorin Colchicine Breast Neoplasms antagonists & inhibitors Cell Survival Adenocarcinoma complications Interferons Antineoplastic Combined Chemotherapy Protocols Cell Division Research Intravesical Administration blood Camptothecin Tretinoin Mycobacterium bovis toxicity Human Herpesvirus 8 Fibroblasts Transitional Cell Carcinoma Acute Disease NF-kappa B Retinoids Cell Line Polyacrylamide Gel Electrophoresis P-Glycoprotein Cyclins Oxidative Stress Bladder Neoplasms Trans-Activation (Genetics) Proportional Hazards Models Cryotherapy Animal Disease Models Genetic Vectors Prostatic Neoplasms Sarcoma Interferon Alfa-2a Nude Mice Adenosine Triphosphate Phosphotransferases Trimetrexate Cytoprotection Viral Load Reverse Transcriptase Polymerase Chain Reaction etiology Enzyme-Linked Immunosorbent Assay Cholecystitis biosynthesis Protein Isoforms Feasibility Studies Isoenzymes methods Inhibitory Concentration 50 Randomized Controlled Trials Japan Cerulenin Microtubules Practice Guidelines Combination Drug Therapy Highly Active Antiretroviral Therapy Antineoplastic Antibiotics cdc Genes Gallbladder Neoplasms Retrospective Studies Antineoplastic Antimetabolites Recombinant Proteins US Gov't Support-Non-PHS Neoplasm Drug Resistance Phytogenic Antineoplastic Agents Drug Combinations Residual Neoplasm Anthracyclines Sulfhydryl Compounds Phosphonoacetic Acid Liposomes Neoplasm Transplantation Tegafur Mesothelioma Transfection radiotherapy KB Cells DNA Fragmentation Anticarcinogenic Agents Immunologic Adjuvants Adjuvant Chemotherapy Vinblastine Hela Cells Physical Examination Paraffin Embedding Multiple Drug Resistance Neoplasm Proteins Respiratory Tract Neoplasms Gene Expression Regulation HT29 Cells Mesothelial Neoplasms
Last updated on Wednesday, February 05, 2020